Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.

S J Cryz; E Fürer; A S Cross; A Wegmann; R Germanier; J C Sadoff

doi:10.1172/JCI113062

Find articles by Cryz, S. in: JCI | PubMed | Google Scholar

Find articles by Fürer, E. in: JCI | PubMed | Google Scholar

Find articles by Cross, A. in: JCI | PubMed | Google Scholar

Find articles by Wegmann, A. in: JCI | PubMed | Google Scholar

Find articles by Germanier, R. in: JCI | PubMed | Google Scholar

Find articles by Sadoff, J. in: JCI | PubMed | Google Scholar

Published in Volume 80, Issue 1 on July 1, 1987
J Clin Invest. 1987;80(1):51–56. https://doi.org/10.1172/JCI113062.
© 1987 The American Society for Clinical Investigation

Published July 1, 1987 - Version history

Lipid A-free polysaccharide (PS) isolated from Pseudomonas aeruginosa immunotype 5 lipopolysaccharide (LPS) was covalently coupled to toxin A via reductive amination. The PS-toxin A conjugate was comprised of 29.8% PS and 70.2% toxin A, possessed a molecular weight of greater than 1 X 10(6), was nontoxic for animals and was nonpyrogenic for rabbits at a dose of 50 micrograms/kg body wt when administered intravenously. The conjugate evoked only mild, transient reactions upon subcutaneous administration to human volunteers. Vaccination engendered immunoglobulin G (IgG) antibody, which neutralized the cytotoxic effect of toxin A and promoted the uptake and killing of P. aeruginosa in the presence of human polymorphonuclear leukocytes. Passively transferred IgG isolated from the serum of immunized donors was far more effective at preventing fatal P. aeruginosa burn wound sepsis than paired preimmunization serum. These studies establish the potential usefulness of such a PS-toxin A conjugate as a vaccine against P. aeruginosa.

Click on an image below to see the page. View PDF of the complete article